We propose a model in which I148M and CGI-58 function at the nexus of two pathways critical for clearing hepatic TG β lipolysis and VLDL secretion β contributing to our understanding of how I148M increases risk for fatty liver disease.
Thank you to the co-authors and my postdoc mentor, Ray Deshaies!
07.10.2025 04:31 β
π 0
π 0
π¬ 0
π 0
Membrane fluidity is a biophysical property that is important for the biogenesis and secretion of VLDLs, which require substantial membrane deformations and changes along the secretory pathway. As a result of impaired VLDL secretion, TG builds up intracellularly in lipid droplets... Thread π§΅ 4/5
07.10.2025 04:31 β
π 0
π 0
π¬ 1
π 0
ApoB is the main scaffolding protein found in all very low-density lipoprotein (VLDL) particles. We found that, through its sequestration of the lipolytic activator ABHD5/CGI-58, I148M causes a shift in cellular lipid composition that causes reduced membrane fluidity... Thread π§΅ 3/5
07.10.2025 04:31 β
π 0
π 0
π¬ 1
π 0
However, it has proven challenging to elucidate the function of the wild-type protein and what goes awry with I148M to cause hepatic triglyceride (TG) accumulation.
Here, my colleagues and I show that liver cells expressing endogenous I148M have impaired secretion of ApoB...
Thread π§΅ 2/5
07.10.2025 04:31 β
π 0
π 0
π¬ 1
π 0
Really inspiring talk! Thank you.
14.04.2025 01:15 β
π 0
π 0
π¬ 0
π 0
Looking forward to engaging presentations and discussions at #ASBMB25! Iβll be by poster 270 (Abstract 2651) on Sunday highlighting some of our work on the biological function of the strongest known genetic risk factor for fatty liver disease worldwide, PNPLA3-I148M β stop by if youβre interested
10.04.2025 21:02 β
π 5
π 2
π¬ 0
π 0
Opinion | Covidβs Deadliest Effect Took Five Years to Appear (Gift Article)
What once belonged to all of us now belongs to corporations.
βBack then, the overwhelming public sentiment was: never again. Today, it seems: never what?ββSiddhartha Mukherjee
Exceptional essay
Gift link
www.nytimes.com/2025/03/10/o...
16.03.2025 15:58 β
π 331
π 111
π¬ 12
π 17
It's an honor to share this year's Passano Award with Ray Deshaies, Ph.D. for the development of PROTACs, a new therapeutic modality that targets proteins for degradation via co-opting the cellular protein recycling machinery.
11.03.2025 11:49 β
π 51
π 2
π¬ 1
π 0